Galactose-Functionalized Affinity Resin for Glycosidase Purification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for purifying glycoside-cleaving enzymes like α-Gal A, GCB, and GAA are cumbersome, requiring multi-step processes and costly elution solutions, and are not easily scalable.
Innovation Solution
Development of an affinity resin functionalized with small molecule ligands that can bind and purify glycoside-cleaving enzymes directly from conditioned cell medium without manipulation, using a resin matrix with specific functional groups and linkers, allowing for efficient elution with buffers like Tris.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional affinity chromatography methods using Concanavalin A or immobilized thio-α-galactoside are used to purify α-Gal A, then purification can be achieved, but the process requires multi-step manipulation of raw material and costly elution solutions
Solution Approach 1:
The patent changes the chemical parameter of the affinity ligand from complex carbohydrates (Concanavalin A) or thio-α-galactoside to simple galactose molecules. This parameter change simplifies the elution process - galactose can be easily removed by dilution or simple buffer changes, eliminating the need for costly elution solutions and multi-step manipulation while maintaining high purification purity
Solution Approach 2:
The patent employs inexpensive galactose molecules as the affinity ligand instead of expensive Concanavalin A or thio-α-galactoside. Galactose is a cheap, readily available sugar that can be used as a disposable elution agent, eliminating the need for costly specialized elution solutions and simplifying the overall purification process
2Manufacturing precision
If conventional affinity chromatography methods are used to purify α-Gal A, then purification can be achieved, but the method is not easily scalable
Solution Approach 1:
The patent changes the affinity ligand from complex, expensive molecules to simple, inexpensive galactose. This parameter change enables scalability because galactose can be easily formulated at high concentrations in large volumes without prohibitive cost, allowing the purification process to be scaled up from laboratory to industrial production while maintaining high purity
3Manufacturing precision
If conventional affinity chromatography requiring multi-step manipulation is used, then purification can be achieved, but time and cost efficiency are reduced
Solution Approach 1:
The patent extracts the essential binding function from complex systems (Concanavalin A, thio-α-galactoside) and isolates it to simple galactose molecules. This extraction eliminates unnecessary complexity and steps - galactose binding and elution can be performed in a single chromatography step without multi-step manipulation, significantly reducing processing time while maintaining purification purity
Solution Approach 2:
The patent employs galactose, which naturally occurs in many buffers and cell culture media. This means the elution agent is already present in the system, eliminating the need for specialized preparation and handling of complex elution solutions. The system essentially uses what is already available, reducing time and complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The affinity resin achieves high purity (>95%) and scalability, maintaining performance even after exposure to NaOH, with a binding capacity of up to 80 mL of conditioned medium per mL of resin, facilitating cost-effective enzyme production for therapies.
Implementation Method 1
affinity resin functionalized with small molecule inhibitors of glycoside-cleaving enzymes... binding the glycoside-cleaving enzyme to the affinity resin
Data Source
AI summary
The invention relates to an affinity resin functionalized with small molecule inhibitors of glycoside-cleaving enzymes, e.g., α-galactosidase A (α-Gal A), glucocerebrosidase (GCB), β-galactosidase, and acid alpha-glucosidase (GAA), and a method for purifying glycoside-cleaving enzymes produced in a cell line using the small molecule inhibitor-functionalized affinity resin.